Drug General Information
Drug ID	D01FUC
Former ID	DIB014573
Drug Name	Exatecan
Synonyms	Exatecan mesylate; DX-8951; DX-8951a; DX-8951f; UM-1; UM-2
Drug Type	Small molecular drug
Indication	Solid tumours [ICD9: 140-199, 210-229; ICD10:C00-D48]		Phase 3	[521494]
Company	Daiichi Seiyaku Co Ltd
Structure		Download 2D MOL 3D MOL
Formula	C24H22FN3O4
Canonical SMILES	n12c(c3c(c4c5c(c(c(cc5n3)F)C)CC[C@@H]4N)C2)cc2c(c1=O)CO<br />C(=O)[C@]2(O)CC
PubChem Compound ID	151115
Target and Pathway
Target(s)	Toposisomerase-1	Target Info	Inhibitor	[526228]
NetPath Pathway	IL2 Signaling Pathway
PANTHER Pathway	DNA replication
Pathway Interaction Database	Caspase Cascade in Apoptosis
WikiPathways	Integrated Pancreatic Cancer Pathway
References
Ref 521494	ClinicalTrials.gov (NCT00023972) Gemcitabine With or Without Exatecan Mesylate in Treating Patients With Locally Advanced or Metastatic Pancreatic Cancer. U.S. National Institutes of Health.
Ref 526228	Phase I study of topoisomerase I inhibitor exatecan mesylate (DX-8951f) given as weekly 24-hour infusions three of every four weeks. Clin Cancer Res. 2001 Dec;7(12):3963-70.

If You Find Any Error in Data or Bug in Web Service, Please Kindly Report It to Dr. Zhou and Dr. Zhang.